Paper - WANFANG MED ONLINE

You Position: Home > Paper

Research progress on cardiorenal protection of sodium-glucose cotransporter 2 inhibitors

( views:72, downloads:70 )

Author:: No author available

Journal Title:: China Medicine

Issue:: 1

DOI:: 10.3760/j.issn.1673-4777.2023.01.029

Key Word:: 钠-葡萄糖共转运蛋白2抑制剂;糖尿病;心肾保护作用

Abstract：钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂是一种新型降糖药物,具有高选择性和特异性,可减少近曲小管对葡萄糖的重吸收,增加尿葡萄糖排出,从而达到降低血糖的目的.在治疗过程中发现,SGLT-2抑制剂在控制血糖的同时,对心脏及肾脏也产生保护作用.SGLT-2抑制剂可以通过降低患者体质量、改善能量代谢及降低血压等机制对心肾产生一定的积极作用.本综述简要阐述了SGLT-2抑制剂在临床诊疗过程中的重要地位及在心脏、肾脏方面所发挥的保护作用.

Reference

[1]周冰青.钠—葡萄糖共转运蛋白1在心血管疾病中作用的研究进展[J].2022,21(8).
[2]魏明明,宋欣瑜,任耀龙,等.钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭临床治疗中的研究进展[J].2022,17(7).
[3]Elserafy Ahmed S.,Reda Ashraf,Farag Elsayed,etc.Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction[J].2021,41(12).
[4]Zhao, Min,Sun, Shusen,Huang, Zhenguang,etc.Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury[J].2021,16(1).
[5]Wiviott, S. D.,Raz, I.,Bonaca, M. P.,etc.Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes[J].2019,380(4).
[6]Kim So Ra,Lee Sang-Guk,Kim Soo Hyun,etc.SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease[J].2020,11(1).
[7]Aubert, Gregory,Martin, Ola J.,Horton, Julie L.,etc.The Failing Heart Relies on Ketone Bodies as a Fuel[J].2016,133(8).
[8]Ehrenkranz JR,Roth J,Lewis NG,etc.Phlorizin: a review.[J].2005,21(1).
[9]Kimura, Genjiro.Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure[J].2016,80(11).
[10]Matsushita K,Blecker S,Pazin Filho A,etc.The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study.[J].2010,59(8).
[11]Cherney, David Z. I.,Fitchett, David H.,Husain, Mansoor,etc.Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications[J].2016,134(10).
[12]Cho, N. H.,Makaroff, L. E.,Fernandes, J. D. da Rocha,etc.IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040[J].2017,128.
[13]Hattori Yoshiyuki.Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization[J].2020,25(3).
[14]Hidekatsu, Yanai,Hisayuki, Katsuyayama.A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production.[J].2017,9(2).
[15]Bernard, Zinman,Christoph, Wanner,John M, Lachin,etc.Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.[J].2015,373(22).
[16]George, Jyothis T.,Schmoor, Claudia,Hantel, Stefan,etc.How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial[J].2018,41(2).
[17]Tuo Han,Yajie Fan,Jie Gao,etc.Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice[J].2021,10(1).
[18]Ferrannini,E.,Solini,A..SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects[J].2012,8(8).
[19].Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients[J].2013,126(10).
[20]Butler Javed,Hamo Carine E.,Filippatos Gerasimos,etc.The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors[J].2017,19(11).
[21]Butler, Javed,Packer, Milton,Greene, Stephen J.,etc.Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus A Critical Evaluation of Clinical and Regulatory Issues[J].2019,140(25).
[22]Zhang, Luxia,Zhao, Ming-Hui,Wang, Haibo.Trends in Chronic Kidney Disease in China[J].2016,375(9).
[23].Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1·9 million people[J].2015,3(2).
[24]Dutka, Mieczyslaw,Bobinski, Rafal,Ulman-Wlodarz, Izabela,etc.Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure[J].2021,26(3).
[25]Kristina.Striepe,Agnes.Jumar,Christian.Ott,etc.Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus[J].2017,136(12).
[26].Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020[J].2020,43(Suppl.1).
[27]Lin Ding,Yu Xu,Shanshan Liu,etc.Hemoglobin A1c and diagnosis of diabetes[J].2018,10(5).
[28]Zoungas Sophia,Woodward Mark,Li Qiang,etc.Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes[J].2014,57(12).
[29]"name":"American Diabetes Association.Standards of Medical Care in Diabetes--2010[J].2009,33(Supplement_1).
[30]Dhillon Sohita.Dapagliflozin: A Review in Type 2 Diabetes[J].2019,79(10).
[31]Briand, Francois,Mayoux, Eric,Brousseau, Emmanuel,etc.Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism[J].2016,65(7).
[32]Alessandra, Dei Cas,Sadiya S, Khan,Javed, Butler,etc.Impact of diabetes on epidemiology, treatment, and outcomes of patients with?heart failure.[J].2015,3(2).
[33]Carina,Iskander,David Z,Cherney,Kristin K,Clemens,etc.Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study.[J].2020,192(14).
[34]A. T. Layton,V. Vallon.Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases[J].2018,222(4).
[35]Andrea V. Haas,Marie E. McDonnell.Pathogenesis of Cardiovascular Disease in Diabetes[J].2018,47(1).
[36]Packer Milton.Do sodium‐glucose co‐transporter‐2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis[J].2018,20(6).
[37]Lam, Carolyn S. P.,Voors, Adriaan A.,de Boer, Rudolf A.,etc.Heart failure with preserved ejection fraction: from mechanisms to therapies[J].2018,39(30).
[38]Mima, Akira.Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease[J].2018,32(7).
[39]Hafiz Imran,William Nester,Islam Y. Elgendy,etc.Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism[J].2020,52(5).